In AD mice treated between 3 and 12 months, the GFAP immunoreactivity decreased in AD mice treated with viniferin although this was not statistically significant (−27% compared to PEG-treated mice) (Supplementary Figure 3C). Here, GFAP is linked to Alzheimer disease.